VVOS Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2019βFY2025
Vivos Therapeutics, Inc. had $17.4M of revenue in fiscal 2025, up 16.0% on the year before. Over five years, revenue changed +5.9% a year on average.
Last close Β· Oct 23, 2026
$0.13
0.9%Hi! I read Vivos Therapeutics, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+16.0%
Yes. Sales grew 16.0% last year.
Does it make a profit?
β121.4%
No. It lost money last year.
Does profit turn into cash?
β100.9%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· Vivos Therapeutics, Inc. had $17.4M of revenue in fiscal 2025, up 16.0% on the year before. Over five years, revenue changed +5.9% a year on average. Its operating margin was β114.1%, down 39.7Β pts: of every 100 in sales, about β114 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Vivos Therapeutics, Inc. lost $21.2M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$17.6M in fiscal 2025, β100.9% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders bought $1.8M of shares on the open market and sold none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$1.8M
1 insider
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | V-Co Investors 3 LLC10% owner | Bought | 1,353,625 | $1.34 | $1.8M | Form 4 |
Can it carry its debts, and how well does it use its money?
KIRA Β· Vivos Therapeutics, Inc. has $1.1M more cash than debt.
Cash, debt and the ratios that show how comfortably Vivos Therapeutics, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $24.0M | $3.5M | $1.6M | $6.3M | $2.0M |
| Debt incl. finance leases | $1.3M | β | $1.2M | $1.2M | $0.9M |
| Debt / equity | 0.0x | β | 2.9x | 0.2x | β |
| Interest coverage | β1,455.9x | β | β | β | β14.2x |
| Current ratio | 3.6x | 0.8x | 0.3x | 1.5x | 0.2x |
| Quick ratio | 3.6x | 0.8x | 0.3x | 1.5x | 0.2x |
| Total assets | $33.7M | $13.7M | $10.7M | $15.3M | $25.2M |
| Total liabilities | $8.2M | $8.9M | $10.3M | $7.3M | $26.7M |
| Shareholders' equity | $25.5M | $4.8M | $0.4M | $8.0M | β$1.5M |
| Net debt (β = net cash) | β$22.8M | β | β$0.4M | β$5.1M | β$1.1M |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Vivos Therapeutics, Inc. passes 3 of 9 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β |
| F-score | β / 3 | 5 / 9 | 3 / 9 | 3 / 8 | 3 / 8 | 4 / 9 | 3 / 9 |
| Accruals ratio | β71.7% | β38.8% | β15.4% | β18.0% | β13.4% | 12.0% | β29.2% |
| Altman Z'' | β25.97 | β2.38 | β2.30 | β31.24 | β42.01 | β24.92 | β25.19 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $11.4M | $13.1M | $16.9M | $16.0M | $13.8M | $15.0M | $17.4M |
| Gross profit | $8.7M | $10.4M | $12.6M | $10.0M | $8.3M | $9.0M | $10.5M |
| Research and development | β | β | $0.2M | $0.2M | $0.1M | $0.1M | $0.1M |
| Operating income | β$10.6M | β$12.0M | β$20.4M | β$25.0M | β$17.3M | β$11.2M | β$19.9M |
| Interest expense | $0.1M | $0.1M | $0.0M | β | β | β | $1.4M |
| Pretax income | β$10.8M | β$12.1M | β$20.3M | β$23.8M | β$13.6M | β$11.1M | β$21.2M |
| Net income | β$10.8M | β$12.1M | β$20.3M | β$23.8M | β$13.6M | β$11.1M | β$21.2M |
| Net income to common | β$11.8M | β$18.0M | β$20.3M | β$23.8M | β$13.6M | β$11.1M | β$21.2M |
| Diluted EPS | β$0.95 | β$1.40 | β$0.96 | β$25.90 | β$11.14 | β$2.22 | β$2.07 |
| Diluted shares | 0.01B | 0.01B | 0.02B | 0.00B | 0.00B | 0.01B | 0.01B |
| Cash flow | |||||||
| Cash from operations | β$5.3M | β$5.7M | β$15.7M | β$19.6M | β$11.9M | β$12.7M | β$15.3M |
| Capital expenditure | $0.2M | $0.1M | $2.4M | $0.9M | $0.8M | $0.6M | $2.3M |
| Free cash flow | β$5.5M | β$5.8M | β$18.1M | β$20.5M | β$12.7M | β$13.3M | β$17.6M |
| Depreciation and amortization | $0.8M | $0.7M | $0.7M | $0.7M | $0.6M | $0.6M | $1.3M |
| Stock-based compensation | $2.0M | $2.2M | $2.7M | $2.4M | $1.1M | $0.8M | $0.7M |
| Acquisitions | β | β | $0.2M | β | β | β | β |
| Balance sheet | |||||||
| Cash and short-term investments | $0.5M | $18.2M | $24.0M | $3.5M | $1.6M | $6.3M | $2.0M |
| Total debt | $3.7M | $1.3M | $1.3M | β | $1.2M | $1.2M | $0.7M |
| Finance lease liabilities | β | β | β | β | β | β | $0.2M |
| Current assets | $2.0M | $20.4M | $27.3M | $5.4M | $2.5M | $7.5M | $4.4M |
| Current liabilities | $9.1M | $7.8M | $7.5M | $6.8M | $7.3M | $5.0M | $18.1M |
| Property and equipment, net | $1.1M | $0.9M | $2.8M | $3.1M | $3.3M | $3.3M | $3.8M |
| Goodwill | $2.7M | $2.7M | $2.8M | $2.8M | $2.8M | $2.8M | $8.6M |
| Intangible assets | $0.7M | $0.3M | $0.3M | $0.3M | $0.4M | $0.4M | $4.0M |
| Total assets | $7.6M | $25.3M | $33.7M | $13.7M | $10.7M | $15.3M | $25.2M |
| Total liabilities | $9.2M | $8.4M | $8.2M | $8.9M | $10.3M | $7.3M | $26.7M |
| Shareholders' equity | β$2.9M | $16.9M | $25.5M | $4.8M | $0.4M | $8.0M | β$1.5M |
| Margins | |||||||
| Gross margin | 76.0% | 79.7% | 74.6% | 62.5% | 59.9% | 60.0% | 60.4% |
| Operating margin | β92.8% | β92.1% | β120.7% | β156.2% | β125.3% | β74.3% | β114.1% |
| EBITDA margin | β86.2% | β86.7% | β116.4% | β152.0% | β120.8% | β70.5% | β106.5% |
| Net margin | β94.4% | β92.3% | β120.2% | β148.8% | β98.4% | β74.1% | β121.4% |
| FCF margin | β48.4% | β44.4% | β107.4% | β128.0% | β92.4% | β88.2% | β100.9% |
| Returns | |||||||
| Return on capital | β2,812.5% | β951,160.0% | β580.5% | β | β | β304.9% | β |
| Return on capital employed | 685.9% | β68.9% | β77.9% | β362.4% | β502.6% | β108.4% | β281.1% |
| Return on equity | β | β172.6% | β95.6% | β157.2% | β521.2% | β266.3% | β655.0% |
| Return on assets | β142.4% | β73.3% | β68.8% | β100.6% | β111.1% | β85.6% | β104.7% |
| Return on tangible equity | β | β128.7% | β90.8% | β1,439.9% | β | β236.8% | β |
| Growth | |||||||
| Revenue growth | β | 14.7% | 29.2% | β5.1% | β13.9% | 8.9% | 16.0% |
| Share count change | β | 4.4% | 65.0% | β95.7% | 32.5% | 311.7% | 104.7% |
| Financial health | |||||||
| Debt / equity | β | 0.1x | 0.0x | β | 2.9x | 0.2x | β |
| Interest coverage | β76.7x | β125.4x | β1,455.9x | β | β | β | β14.2x |
| Current ratio | 0.2x | 2.6x | 3.6x | 0.8x | 0.3x | 1.5x | 0.2x |
| Quick ratio | 0.2x | 2.6x | 3.6x | 0.8x | 0.3x | 1.5x | 0.2x |
| Capital allocation | |||||||
| Capex / revenue | 1.5% | 0.9% | 14.2% | 5.8% | 5.8% | 3.8% | 13.4% |
| Stock comp / revenue | 17.4% | 16.6% | 15.7% | 15.0% | 8.0% | 5.1% | 3.8% |
| Quality scores | |||||||
| Piotroski F-score | β | 5.0 | 3.0 | 3.0 | 3.0 | 4.0 | 3.0 |
| Altman Z'' | β26.0 | β2.4 | β2.3 | β31.2 | β42.0 | β24.9 | β25.2 |
| Accruals ratio | β71.7% | β38.8% | β15.4% | β18.0% | β13.4% | 12.0% | β29.2% |
Source: SEC EDGAR XBRL filings (CIK 0001716166). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
